GRIN-related complex neurodevelopmental disorder
MONDO:1060138A group of neurological and neurodevelopmental disorders caused by pathogenic variants in genes encoding subunits of the N-methyl-D-aspartate (NMDA) receptor, including GRIN1, GRIN2A, GRIN2B, and GRIN2D. These disorders are associated with a spectrum of symptoms such as developmental delay, intellectual disability, epilepsy, movement disorders, speech and language impairment, and neuropsychiatric features. The clinical presentation and severity vary depending on the specific gene and mutation involved.
3 clinical trials for this condition and its sub-types, 2 tagged with GRIN-related complex neurodevelopmental disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of GRIN-related complex neurodevelopmental disorder
-
5 sub-types
- GRIN2A-related developmental and/or epileptic encephalopathy with spike-wave activation in sleep 0 trials
- GRIN2A-related rolandic epilepsy-speech dyspraxia syndrome 0 trials
- GRIN2A-related self-limited epilepsy with centrotemporal spikes 0 trials
- Landau-Kleffner syndrome 0 trials
- Early-onset epileptic encephalopathy and intellectual disability due to GRIN2A mutation 0 trials
-
2 sub-types
-
Promising new drug targets seizures in rare GRIN disorder
Disease control Recruiting nowThis study tests a drug called radiprodil in people with GRIN-related neurodevelopmental disorder, a rare genetic condition that often causes seizures and developmental delays. The trial includes two groups: one with frequent seizures and one with fewer or no seizures. Participan…
Phase 3 • Sponsor: GRIN Therapeutics, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a simple amino acid ease GRIN disorder symptoms? new trial aims to find out.
Disease control Recruiting nowThis study tests whether L-serine, a natural amino acid taken as a supplement, can improve overall functioning in children and young adults (ages 2-30) with GRIN-related neurodevelopmental disorders caused by certain gene variants. Each participant will receive both L-serine and …
Phase 3 • Sponsor: Meyer Children's Hospital IRCCS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC